<DOC>
	<DOCNO>NCT00834678</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , bendamustine , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving bendamustine together erlotinib may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose give bendamustine together erlotinib treat patient stage IIIB , stage IIIC , stage IV breast cancer .</brief_summary>
	<brief_title>Bendamustine Erlotinib Treating Patients With Stage IIIB , Stage IIIC , Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine phase II dose ass toxicity bendamustine hydrochloride erlotinib hydrochloride patient triple-receptor ( estrogen receptor , progesterone receptor , HER-2 ) -negative , stage IIIB , IIIC , IV breast cancer . ( Phase I ) - To determine efficacy regimen patient . ( Phase II ) Secondary ( Correlative ) - To assess correlation tumor EGFR expression EGFR gene amplification treatment efficacy toxicity . - To assess difference treatment efficacy basal-like non-basal-like cancer . - To assess difference treatment efficacy tumor without expression DNA damage-response ( DDR ) checkpoint protein . - To assess difference activation state DDR checkpoint protein base breast cancer subtype . OUTLINE : This multicenter , phase I dose-escalation study follow phase II study . Patients receive bendamustine hydrochloride IV 30 minute day 1-2 oral erlotinib hydrochloride daily day 5-21 . Treatment repeat every 28 day least 6 course absence disease progression unacceptable toxicity . Patients evidence disease progression may continue daily single-agent oral erlotinib hydrochloride day 1-28 . Treatment continue every 28 day absence disease progression unacceptable toxicity . Breast cancer tissue block prior procedure obtain correlative study . After tissue microarray ( TMA ) TMA map prepare , TMA slide use hematoxylin eosin ( H &amp; E ) staining , FISH , IHC . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer meet 1 follow criterion : Unresectable stage IIIB IIIC disease Stage IV disease Must negative following : Estrogen receptor ( &lt; 10 % ) Progesterone receptor ( &lt; 10 % ) HER2 ( negative FISH , IHC 0 1+ , IHC +2 negative FISH ) Measurable evaluable disease No symptomatic progressive CNS ( central nervous system ) metastases Previously treat CNS metastasis allow provide follow criterion meet : At least 8 week since prior radiation brain CNS metastases No concurrent steroids No leptomeningeal disease PATIENT CHARACTERISTICS : Menopausal status specify ECOG ( Eastern Cooperative Oncology Group ) performance status 02 Life expectancy ≥ 6 month WBC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Creatinine clearance &gt; 40 mL/min Normal electrolytes ( i.e. , Na , K , Ca normal ; minor deviation allow impact patient safety clinical judgment treat physician ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 time ULN presence document liver metastasis ) Alkaline phosphatase ≤ 2.5 time ULN ( ≤ 5 time ULN presence liver bone metastasis ) Not pregnant nursing Fertile patient must use effective barrier contraception No uncontrolled intercurrent illness No active infection require systemic therapy Able swallow oral medication medical problem prior surgery may interfere absorption oral medication include follow : Uncontrolled nausea , vomit , diarrhea Lack physical integrity upper gastrointestinal tract Malabsorption syndrome No known hypersensitivity bendamustine hydrochloride , mannitol , erlotinib hydrochloride No prior malignancy past 5 year except adequately treat basal cell squamous cell skin carcinoma , adequately treated stage III cancer patient complete remission PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior adjuvant neoadjuvant chemotherapy 1 prior chemotherapy regimen metastatic setting allow provide recovered acute toxicity No prior bendamustine hydrochloride EGFRdirected therapy No concurrent antineoplastic treatment , include radiotherapy , chemotherapy , biological therapy , hormonal therapy , immunotherapy , gene therapy , surgery Intravenous bisphosphonates allow No concurrent antiretroviral therapy HIVpositive patient No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
	<keyword>triple-negative breast cancer</keyword>
</DOC>